TBPH Insider: 6,989 RSU Shares Withheld for Taxes; 208,001 Owned

Rhea-AI Filing Summary

Theravance Biopharma insider report: Miller Aine, SVP, Development & Head of IRE Office and an officer of Theravance Biopharma (TBPH), had 6,989 ordinary shares withheld on 08/20/2025 to satisfy tax obligations arising from the vesting of previously granted restricted stock units. The withholding was executed with the issuer and was not an open-market sale. After the transaction, the reporting person beneficially owned 208,001 shares. The per-share price for the withheld shares is reported as $13.39. The Form 4 was signed by an attorney-in-fact on 08/22/2025.

Insights

Securities Analyst

TL;DR: Routine tax-withholding on RSU vesting; not an open-market disposition and likely neutral for investors.

The filing documents a common administrative transaction: 6,989 shares were withheld to cover taxes when RSUs vested, at a reported per-share price of $13.39. Because the shares were withheld by the issuer rather than sold on the open market, there is no direct signaling of insider liquidity preference or market pressure. The remaining beneficial ownership of 208,001 shares provides context on the officer's ongoing stake, which appears stable after the withholding. No additional share grants, option exercises, or derivative transactions are reported.

Corporate Governance Expert

TL;DR: Administrative withholding for tax compliance; reflects standard equity compensation mechanics and raises no governance concerns.

This Form 4 shows a withholding event tied to RSU vesting rather than an independent sale. Such withholdings are typical to satisfy tax obligations and are processed internally by the issuer. The report identifies the reporting person as an officer (SVP, Development & Head of IRE Office) and confirms continued beneficial ownership of 208,001 shares, indicating alignment with shareholder interests remains. There are no indications of unusual timing, related-party transactions, or changes to executive roles in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Aine

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, DEV & HEAD OF IRE OFFICE

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/20/2025		F		6,989(1)	D	$13.39	208,001	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

	/s/ Brett A. Grimaud, Attorney-in-Fact	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Miller Aine report on the TBPH Form 4?

The Form 4 reports that 6,989 ordinary shares were withheld on 08/20/2025 to satisfy tax obligations from vested restricted stock units.

Was the share withholding an open-market sale for TBPH?

No. The filing states the share withholding was with the issuer and did not involve an open market transaction.

How many TBPH shares does the reporting person beneficially own after the transaction?

After the transaction the reporting person beneficially owned 208,001 shares.

At what price were the withheld TBPH shares reported?

The withheld shares are reported at a per-share price of $13.39.

What is Miller Aine's role at Theravance Biopharma as listed on the filing?

The filing lists Miller Aine as an Officer, specifically SVP, Development & Head of IRE Office.